Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ASN 2026
Finerenone Safety and Effectiveness Across CKD Stages in Type 2 Diabetes: Analysis of Four US Databases from the FOUNTAIN Platform
- Based on the analysis of these four US data sources, finerenone initiation in individuals with T2D and CKD was associated with early reductions in albuminuria and a predictable hyperkalemia safety profile across all CKD stages.
- These findings support that finerenone is effective and has a predictable safety profile across the CKD spectrum in routine practice
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
